Your browser doesn't support javascript.
loading
A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies.
Shibata, Stephen; Raubitschek, Andrew; Leong, Lucille; Koczywas, Marianna; Williams, Lawrence; Zhan, Jiping; Wong, Jeffrey Y C.
Afiliação
  • Shibata S; City of Hope, Duarte, California 91010, USA. sshibata@coh.org
Clin Cancer Res ; 15(8): 2935-41, 2009 Apr 15.
Article em En | MEDLINE | ID: mdl-19351765
PURPOSE: To determine the maximum tolerated dose of combined therapy using an yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody with gemcitabine in patients with advanced CEA-producing solid tumors. EXPERIMENTAL DESIGN: The chimeric human/murine cT84.66 is an anti-CEA intact IgG1, with high affinity and specificity to CEA. This was given at a fixed yttrium-90-labeled dose of 16.6 mCi/m(2) to subjects who had and an elevated CEA in serum or in tumor by immunohistochemistry. Also required was a tumor that imaged with an (111)In-labeled cT84.66 antibody. Patients were treated with escalating doses of gemcitabine given i.v. over 30 minutes on day 1 and 3 after the infusion of the yttrium-90-labeled antibody. Patients were treated in cohorts of 3. The maximum tolerated dose was determined as the highest level at which no >1 of 6 patients experienced a dose limiting toxicity. RESULTS: A total of 36 patients were enrolled, and all but one had prior systemic therapy. The maximum tolerated dose of gemcitabine in this combination was 150 mg/m(2). Dose limiting toxicities at a gemcitabine dose of 165 mg/m(2) included a grade 3 rash and grade 4 neutropenia. One partial response was seen in a patient with colorectal cancer, and 4 patients had a >50% decrease in baseline CEA levels associated with stable disease. Human antichimeric antibody responses were the primary reason for stopping treatment in 12 patients. CONCLUSIONS: Feasibility of combining gemcitabine with an yttrium-90-labeled anti-CEA antibody is shown with preliminary evidence of clinical response.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos Organometálicos / Antígeno Carcinoembrionário / Desoxicitidina / Neoplasias Gastrointestinais / Anticorpos Monoclonais Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2009 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos Organometálicos / Antígeno Carcinoembrionário / Desoxicitidina / Neoplasias Gastrointestinais / Anticorpos Monoclonais Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2009 Tipo de documento: Article